Brian Jarrett Mcmahon

Brian Jarrett Mcmahon's AcademicInfluence.com Rankings

Medical

#1883

World Rank

#2264

Historical Rank

Public Health

#255

World Rank

#264

Historical Rank

Epidemiology

#297

World Rank

#314

Historical Rank

medical Degrees

Download Badge

Medical

Brian Jarrett Mcmahon's Degrees

PhD Epidemiology University of California, Berkeley
Masters Public Health University of California, Berkeley

Why Is Brian Jarrett Mcmahon Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Brian Jarrett Mcmahon's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 (2015) (5270)
Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 (2016) (4388)
Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015 (2016) (4293)
Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 (2018) (3308)
Chronic hepatitis B: Update 2009 (2009) (2738)
The Global Burden of Cancer 2013. (2015) (2336)
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance (2018) (2204)
Chronic hepatitis B (2001) (1618)
Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 (2018) (1515)
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016 (2018) (899)
Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. (1985) (821)
Chronic hepatitis B: Update of recommendations (2004) (538)
Chronic hepatitis B. (2002) (524)
Chronic hepatitis B (2001) (475)
Negative Immune Regulator Tim-3 Is Overexpressed on T Cells in Hepatitis C Virus Infection and Its Blockade Rescues Dysfunctional CD4+ and CD8+ T Cells (2009) (459)
Serologic and Clinical Outcomes of 1536 Alaska Natives Chronically Infected with Hepatitis B Virus (2001) (432)
Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta‐analysis (2016) (390)
Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: A 16‐year population‐based study (2000) (345)
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. (2019) (329)
Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. (2010) (320)
Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. (1990) (310)
The natural history of chronic hepatitis B virus infection (2009) (298)
Chronic hepatitis B virus infection. (2014) (291)
Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease (1998) (261)
Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta‐analysis (2016) (260)
Present and future therapies of hepatitis B: From discovery to cure (2015) (259)
Antibody Levels and Protection after Hepatitis B Vaccination: Results of a 15-Year Follow-up (2005) (249)
The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B (2009) (246)
Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. (2007) (245)
Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F. (2007) (244)
Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. (2009) (241)
Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus (2010) (233)
Prevalence of autoimmune liver disease in Alaska natives (2002) (230)
Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose. (2016) (212)
Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers (2003) (212)
Natural history of chronic hepatitis B. (2010) (208)
Epidemiology of Hepatitis B Virus Infection and Impact of Vaccination on Disease. (2016) (204)
Reply: Potential conflict of interest: Nothing to report. (2007) (203)
The Relationship among Previous Antimicrobial Use, Antimicrobial Resistance, and Treatment Outcomes for Helicobacter pylori Infections (2003) (200)
Epidemiology and natural history of hepatitis B. (2005) (190)
The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. (1985) (189)
Protection provided by hepatitis B vaccine in a Yupik Eskimo population--results of a 10-year study. (1997) (179)
[AASLD Practice Guidelines. Chronic hepatitis B: update of therapeutic guidelines]. (2004) (176)
Is chronic hepatitis B being undertreated in the United States? (2011) (167)
Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch‐up immunization program (2011) (160)
A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine. (1996) (160)
Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. (2007) (154)
Evolution of Hepatitis C Virus Quasispecies in Hypervariable Region 1 and the Putative Interferon Sensitivity-Determining Region during Interferon Therapy and Natural Infection (1998) (152)
Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. (1989) (151)
Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. (2005) (149)
Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program. (2000) (148)
Spontaneous death of Echinococcus multilocularis: cases diagnosed serologically (by Em2 ELISA) and clinical significance. (1987) (142)
Treatment of children with chronic hepatitis B virus infection in the United States: Patient selection and therapeutic options (2010) (134)
Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance (2018) (133)
Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons. (1992) (133)
Duration of Hepatitis B Immunity in Low Risk Children Receiving Hepatitis B Vaccinations From Birth (2004) (123)
Hepatitis B‐associated polyarteritis nodosa in alaskan eskimos: Clinical and epidemiologic features and long‐term follow‐up (1989) (121)
Persistence of Antibody to Hepatitis B and Protection From Disease Among Alaska Natives Immunized at Birth (2005) (117)
Parasiticidal effect of chemotherapy in alveolar hydatid disease: review of experience with mebendazole and albendazole in Alaskan Eskimos. (1992) (112)
A COMPREHENSIVE PROGRAMME TO REDUCE THE INCIDENCE OF HEPATITIS B VIRUS INFECTION AND ITS SEQUELAE IN ALASKAN NATIVES (1987) (100)
Response to hepatitis B vaccine of persons positive for antibody to hepatitis B core antigen. (1992) (98)
Early detection of primary hepatocellular carcinoma. Screening for primary hepatocellular carcinoma among persons infected with hepatitis B virus. (1985) (94)
Differences in Response to a Hepatitis B Vaccine Booster Dose Among Alaskan Children and Adolescents Vaccinated During Infancy (2005) (94)
Low frequency of p53 mutations observed in a diverse collection of primary hepatocellular carcinomas. (1992) (91)
Hepatitis B virus DNA in persons with isolated antibody to hepatitis B core antigen who subsequently received hepatitis B vaccine. (1998) (91)
The relationship between previous fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection. (2007) (90)
Classification of hepatitis B virus genotype B into 2 major types based on characterization of a novel subgenotype in Arctic indigenous populations. (2007) (81)
Reactivation of Hepatitis B During Immunosuppressive Therapy: Potentially Fatal Yet Preventable (2012) (80)
Immunogenicity of an inactivated hepatitis A vaccine in Alaska Native children and Native and non-Native adults. (1995) (79)
Hepatitis B Vaccination, Screening, and Linkage to Care: Best Practice Advice From the American College of Physicians and the Centers for Disease Control and Prevention (2017) (77)
Hepatitis B virus precore mutation and fulminant hepatitis in the United States. A polymerase chain reaction-based assay for the detection of specific mutation. (1994) (75)
Treatment of chronic hepatitis B virus infection in resource‐constrained settings: expert panel consensus (2011) (73)
Epidemiology and risk factors for hepatitis C in Alaska Natives (2004) (72)
10 Worldwide prevalence and prevention of hepatitis c (2000) (69)
Corrections to AASLD guidelines on chronic hepatitis B (2007) (68)
Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and meta‐analysis (2016) (68)
High rate of spontaneous negativity for hepatitis C virus RNA after establishment of chronic infection in Alaska Natives. (2006) (64)
Seroprevalence of hepatitis B viral markers in 52,000 Alaska Natives. (1993) (63)
SEROLOGICAL MARKERS OF HEPATITIS B VIRUS AND ALPHA-FETOPROTEIN LEVELS PRECEDING PRIMARY HEPATOCELLULAR CARCINOMA IN ALASKAN ESKIMOS (1982) (62)
Prevalence of hepatitis B in selected Alaskan Eskimo villages. (1983) (62)
A research agenda for curing chronic hepatitis B virus infection (2018) (61)
Natural history of chronic hepatitis B - clinical implications. (2008) (61)
Alaska Sentinel Surveillance for Antimicrobial Resistance in Helicobacter pylori Isolates from Alaska Native Persons, 1999–2003 (2006) (59)
Protection provided by hepatitis B vaccine in a Yupik Eskimo population. Seven-year results. (1991) (57)
Characterization of Helicobacter pylori cagA and vacA Genotypes among Alaskans and Their Correlation with Clinical Disease (2011) (56)
Persistence of antibody to hepatitis A virus 10 years after vaccination among children and adults. (2008) (56)
Comparison of serologic tests for the diagnosis and follow-up of alveolar hydatid disease. (1987) (55)
Diagnostic accuracy of a fibrosis serum panel (FIBROSpect II) compared with Knodell and Ishak liver biopsy scores in chronic hepatitis C patients (2006) (53)
Hepatitis C virus dynamics during natural infection are associated with long-term histological outcome of chronic hepatitis C disease. (2007) (53)
Consequences of continuous mebendazole therapy in alveolar hydatid disease--with a summary of a ten-year clinical trial. (1986) (52)
A Longitudinal Hepatitis B Vaccine Cohort Demonstrates Long-lasting Hepatitis B Virus (HBV) Cellular Immunity Despite Loss of Antibody Against HBV Surface Antigen. (2016) (52)
Incidence of hepatocellular carcinoma according to hepatitis B virus genotype in Alaska Native people (2016) (52)
Evaluation of the response to a booster dose of hepatitis B vaccine in previously immunized healthcare workers. (2001) (51)
The diagnosis and treatment of Helicobacter pylori infection in Arctic regions with a high prevalence of infection: Expert Commentary (2015) (50)
The control of hepatitis B virus infection with vaccine in Yupik Eskimos. Demonstration of safety, immunogenicity, and efficacy under field conditions. (1985) (49)
Comparison of different HCV viral load and genotyping assays. (2003) (47)
Immunogenicity of an Inactivated Hepatitis A Vaccine in Infants and Young Children (2007) (47)
Reinfection after successful eradication of Helicobacter pylori: a 2‐year prospective study in Alaska Natives (2006) (47)
Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection. (2010) (46)
Recommendations for Screening, Monitoring, and Referral of Pediatric Chronic Hepatitis B (2009) (46)
Advancing the High Throughput Identification of Liver Fibrosis Protein Signatures Using Multiplexed Ion Mobility Spectrometry* (2014) (45)
The natural history of chronic hepatitis B virus infection. (2004) (44)
Hepatocellular Carcinoma Risk in Alaska Native Children and Young Adults with Hepatitis B Virus: Retrospective Cohort Analysis. (2016) (44)
Albendazole therapy in alveolar hydatid disease: a report of favorable results in two patients after short-term therapy. (1987) (42)
Prevalence and causes of elevated serum aminotransferase levels in a population-based cohort of persons with chronic hepatitis B virus infection. (2014) (42)
Secular trends in hepatitis A virus infection among Alaska Natives. (1993) (42)
Evaluation of seaFAST, a Rapid Fluorescent In Situ Hybridization Test, for Detection of Helicobacter pylori and Resistance to Clarithromycin in Paraffin-Embedded Biopsy Sections (2005) (41)
Hepatitis D outbreak among children in a hepatitis B hyper‐endemic settlement in Greenland (2010) (41)
Primary hepatocellular carcinoma in alaskan natives, 1969–1979 (1981) (39)
EPIDEMIOLOGY OF HEPATITIS B IN TWO ALASKAN COMMUNITIES (1977) (38)
Increases in levels of antibody to hepatitis B surface antigen in an immunized population. (1998) (38)
Alaska Sentinel Surveillance Study of Helicobacter pylori Isolates from Alaska Native Persons from 2000 to 2008 (2011) (38)
Clinical significance of elevated alpha‐fetoprotein in Alaskan Native patients with chronic hepatitis C (2007) (36)
Infection With Hepatitis C Virus Genotype 3 Is an Independent Risk Factor for End‐Stage Liver Disease, Hepatocellular Carcinoma, and Liver‐Related Death (2017) (36)
Chronic Liver Disease among Alaska-Native People, 2003–2004 (2009) (35)
The effect of IM ketorolac tromethamine on bleeding time: a prospective, interventional, controlled study. (2003) (35)
Rates and risk factors for hepatitis B reactivation in a cohort of persons in the inactive phase of chronic hepatitis B-Alaska, 2001-2010. (2013) (35)
Incidence of diabetes mellitus in a population‐based cohort of persons with chronic hepatitis B virus infection (2013) (34)
Clustering of hepatocellular carcinoma in Alaska Native families (1991) (33)
Evaluation of angled bar racks and louvers for guiding silver phase American eels (2003) (33)
Evaluation of Behavior and Survival of Fish Exposed to an Axial-Flow Hydrokinetic Turbine (2015) (33)
Reinfection after successful eradication of Helicobacter pylori in three different populations in Alaska (2014) (32)
Genetic Diversity of Near Genome-Wide Hepatitis C Virus Sequences during Chronic Infection: Evidence for Protein Structural Conservation Over Time (2011) (32)
Impact of immunizations on the disease burden of American Indian and Alaska native children. (2009) (32)
Genetic diversity of hepatitis B virus genotypes B6, D and F among circumpolar indigenous individuals (2013) (32)
Hepatitis A vaccine: immunogenicity following administration of a delayed immunization schedule in infants, children and adults. (2003) (31)
Selecting Appropriate Management Strategies for Chronic Hepatitis B: Who to Treat (2006) (31)
Long-term immunogenicity of hepatitis A virus vaccine in Alaska 17 years after initial childhood series. (2013) (30)
Immunogenicity of the 23-valent pneumococcal polysaccharide vaccine in Alaska Native chronic alcoholics compared with nonalcoholic Native and non-Native controls. (1993) (29)
Risk of end‐stage liver disease, hepatocellular carcinoma, and liver‐related death by fibrosis stage in the hepatitis C Alaska Cohort (2017) (29)
Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children. (2013) (28)
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE (2007) (27)
WGO Guidance for the Care of Patients With COVID-19 and Liver Disease (2020) (27)
Diagnostic accuracy of tests for Helicobacter pylori in an Alaska Native population. (2011) (27)
Mortality caused by chronic liver disease among American Indians and Alaska Natives in the United States, 1999-2009. (2014) (26)
Evolution of hepatocellular carcinoma associated with chronic hepatitis B virus infection in Alaskan Eskimos. (1988) (26)
Viral hepatitis in the Arctic (2004) (26)
Persistence of hepatitis A vaccine induced seropositivity in infants and young children by maternal antibody status: 10‐year follow‐up (2012) (26)
Estimating the Date of Hepatitis C Virus Infection from Patient Interviews and Antibody Tests on Stored Sera (2004) (25)
An Association Between Core Mutations in Hepatitis B Virus Genotype F1b and Hepatocellular Carcinoma in Alaskan Native People (2018) (25)
Nested case–control study: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance (2016) (24)
Immune responses of prematurely born infants to hepatitis B vaccination: results through three years of age. (1998) (24)
Azathioprine metabolite measurements are not useful in following treatment of autoimmune hepatitis in Alaska Native and other non-Caucasian people. (2011) (24)
Primary liver cancer in Alaskan natives 1980–1985 (1987) (24)
Research priorities for the discovery of a cure for chronic hepatitis B: Report of a workshop (2017) (23)
Chronic carriers of hepatitis B virus who clear hepatitis B surface antigen: Are they really “off the hook”? (1998) (23)
p53 is not mutated in hepatocellular carcinomas from Alaska Natives. (1995) (23)
Impact of a statewide childhood vaccine program in controlling hepatitis A virus infections in Alaska. (2010) (22)
Impact of recurrent epidemics of hepatitis a virus infection on population immunity levels: Bristol Bay, Alaska. (2002) (22)
Comparison of enzyme immunoassay with radioimmunoassay for the detection of antibody to hepatitis B core antigen as the only marker of hepatitis b infection in a population with a high prevalence of hepatitis B (1990) (22)
Relationship between level of hepatitis B virus DNA and liver disease: a population-based study of hepatitis B e antigen-negative persons with hepatitis B. (2014) (22)
Hepatitis B virions isolated with antibodies to the pre‐S1 domain reveal occult viremia by PCR in Alaska Native HBV carriers who have seroconverted (2000) (21)
Vasculitis in Eskimos living in an area hyperendemic for hepatitis B. (1980) (20)
Helicobacter pylori infection and markers of gastric cancer risk in Alaska Native persons: a retrospective case-control study. (2014) (20)
Use of Current and New Endpoints in the Evaluation of Experimental Hepatitis B Therapeutics (2017) (20)
Prevalence of hepatitis B virus infection in Tonga: identifying high risk groups for immunization with hepatitis B vaccine. (1986) (20)
Dynamics of Helicobacter pylori-Specific Immunoglobulin G for 2 Years after Successful Eradication of Helicobacter pylori Infection in an American Indian and Alaska Native Population (2006) (19)
Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma : Preponderance of genotype F. Commentary (2007) (18)
A prospective evaluation of 200 upper endoscopies performed in Alaska Native persons (2007) (18)
Antimicrobial resistance among Helicobacter pylori isolates in Alaska, 2000-2016. (2018) (18)
Delayed development of antibody to hepatitis B surface antigen after symptomatic infection with hepatitis B virus (1981) (18)
Treatment eligibility in Alaska Native and American Indian persons with hepatitis C virus infection (2012) (18)
Chronic Hepatitis B in Pregnancy A Workshop Consensus Statement on Screening, Evaluation, and Management, Part 1 (2012) (17)
HBV Genotype: A Significant Risk Factor in Determining Which Patients With Chronic HBV Infection Should Undergo Surveillance for HCC: The Hepatitis B Alaska Study (2021) (17)
Chronic hepatitis B infection: a workshop consensus statement and algorithm. (2011) (17)
Environmental Effects of Hydrokinetic Turbines on Fish: Desktop and Laboratory Flume Studies (2013) (17)
Factors associated with the progression of fibrosis on liver biopsy in Alaska Native and American Indian persons with chronic hepatitis C. (2010) (16)
Severe abdominal vasculitis with hepatitis B antigenemia. (1980) (16)
Viral hepatitis in the Arctic. A review from a Circumpolar Workshop on Viral hepatitis, ICCH13. (2007) (16)
Hepatitis C infection in Alaska Natives with persistently normal, persistently elevated or fluctuating alanine aminotransferase levels (2006) (16)
Results of a general hepatitis C lookback program for persons who received blood transfusions in a neonatal intensive care unit between January 1975 and July 1992. (2007) (16)
Hepatitis-Associated Liver Cancer: Gaps and Opportunities to Improve Care. (2016) (16)
Participant observation of a major design decision in industry (1979) (16)
Strategic use of lamivudine in the management of chronic hepatitis B. (2013) (15)
Combating gastric cancer in Alaska Native people: An expert and community symposium: Alaska Native Gastric Cancer Symposium. (2019) (15)
Persistence of antibody to Hepatitis A virus 20 years after receipt of Hepatitis A vaccine in Alaska (2017) (15)
Genetic and functional heterogeneity of the hepatitis C virus p7 ion channel during natural chronic infection. (2012) (15)
Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C. (2008) (15)
Hepatitis A vaccine immune response 22 years after vaccination (2018) (15)
Investigation of Putative Multisubtype Hepatitis C Virus Infections In Vivo by Heteroduplex Mobility Analysis of Core/Envelope Subgenomes (2008) (15)
Hepatitis B Virus Antibody Levels 7 to 9 Years after Booster Vaccination in Alaska Native Persons (2014) (14)
Response to hepatitis B vaccine in Alaska natives with chronic alcoholism compared with non-alcoholic control subjects. (1990) (14)
Hepatitis B and hepatocellular carcinoma in Eskimo/Inuit population. (1998) (14)
The Effect of Helicobacter pylori Infection on Iron Stores and Iron Deficiency in Urban Alaska Native Adults (2013) (12)
Precise, biomimetic replication of the multiscale structure of intestinal basement membrane using chemical vapor deposition. (2013) (12)
Persistence of seropositivity among persons vaccinated for hepatitis A during infancy by maternal antibody status: 15‐year follow‐up (2016) (11)
Burden and prevention of viral hepatitis in the Arctic region, Copenhagen, Denmark, 22–23 March 2012 (2013) (11)
Hepatitis B‐associated vasculitis in Alaska Natives: viral genotype, clinical and serologic outcome (2007) (11)
Hepatitis B surface antigen (HBsAg): a 40-year-old hepatitis B virus seromarker gets new life. (2010) (11)
Hepatitis A vaccination for post-exposure prophylaxis in persons aged 40 years and older. (2014) (11)
Prevalence and correlates of hepatitis C virus-associated inflammatory arthritis in a population-based cohort. (2017) (10)
Long-term immunogenicity of inactivated hepatitis A vaccine: Follow-up at 15 years (2010) (10)
Internist diagnosis and management of chronic hepatitis B virus infection. (2012) (10)
Cost-effectiveness analysis of hepatocellular carcinoma screening by combinations of ultrasound and alpha-fetoprotein among Alaska Native people, 1983-2012. (2016) (9)
Evaluation of angled bar racks and louvers for guiding lake and shortnose sturgeon (2002) (9)
Observed Changes in Natural Killer and T cell Phenotypes with Evaluation of Immune Outcome in a Longitudinal Cohort Following Sofosbuvir-Based Therapy for Chronic Hepatitis C Infection (2019) (8)
Hepatocellular carcinoma not related to hepatitis B virus infection among Alaska natives. (1999) (8)
Hepatocellular carcinoma in Alaska Eskimos: epidemiology, clinical features, and early detection. (1990) (8)
Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus (vol 31, pg 755, 2011) (2012) (8)
Steatosis and hepatitis C in an Alaska Native/American Indian population (2006) (8)
Results of a hepatitis C general transfusion lookback program for patients who received blood products before July 1992 (2005) (8)
Group A streptococcal meningitis in an infant: report of a case associated with a community outbreak due to M-type 4 organisms. (1979) (7)
Protection and antibody levels 35 years after primary series with hepatitis B vaccine and response to a booster dose (2022) (7)
Presence of cagPAI genes and characterization of vacA s, i and m regions in Helicobacter pylori isolated from Alaskans and their association with clinical pathologies. (2020) (7)
Implementing evidenced-based practice guidelines for the management of chronic hepatitis B virus infection. (2008) (7)
Cascade of Care for Alaska Native People with Chronic Hepatitis C Virus Infection: Statewide Program with High Linkage to Care. (2019) (7)
Autoimmune hepatitis in the Alaska Native population: autoantibody profile and HLA associations (2014) (7)
Photoinitiated chemical vapor deposition of cytocompatible poly(2-hydroxyethyl methacrylate) films. (2014) (7)
No inflammation? No cancer! Clear HBV early and live happily (2010) (6)
Epidemiology of hepatitis B in two Alaska communities. (1977) (6)
H. pylori-associated pathologic findings among Alaska native patients (2018) (6)
Neonatal Calcaneous Osteomyelitis Related to Contaminated Mineral Oil (1977) (6)
Does Incorporating Change in APRI or FIB-4 Indices Over Time Improve the Accuracy of a Single Index for Identifying Liver Fibrosis in Persons With Chronic Hepatitis C Virus Infection? (2016) (6)
Immunogenicity of the hepatitis A vaccine 20 years after infant immunization. (2020) (6)
Risk-Based Prenatal Hepatitis C Testing Practices and Results, Alaska 2013-2016 (2019) (6)
Meeting the WHO and US Goals to Eliminate Hepatitis B Infection by 2030: Opportunities and Challenges (2018) (5)
Immunogenicity of a combined hepatitis B and Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. (1998) (5)
Racial/ethnic disparities in hepatocellular carcinoma incidence and mortality rates in the United States, 1992–2018 (2022) (5)
A prospective study of hepatitis B virus serologic markers and liver enzymes. (1980) (5)
Hepatitis A vaccine immune response 22 years after vaccination. (2018) (5)
Safety and immunogenicity of a combined hepatitis B virus-Haemophilus influenzae type B vaccine formulation in healthy adults. (1993) (5)
Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C (2016) (4)
Role of combination therapy in chronic hepatitis B (2009) (4)
Detection of alpha-fetoprotein and hepatitis-B surface antigen in blood spotted on filter paper: use as a screen for hepatocellular carcinoma in Alaska Natives. (1996) (4)
Editorial Commentary: Sliding Down the Cascade of Care for Chronic Hepatitis B Virus Infection. (2016) (4)
Sepsis due to Streptococcus pneumoniae in a patient with alcoholism who received pneumococcal vaccine. (1999) (4)
Hepatitis A vaccine immunogenicity 25 years after vaccination in Alaska (2020) (4)
Hepatitis B virus replication and tuberculin reactivity: studies in Alaska. (1987) (4)
The changing epidemiology and aetiology of hepatocellular carcinoma from 1969 through 2013 in Alaska Native people (2016) (4)
Cost-effectiveness analysis of hepatocellular carcinoma screening by combinations of ultrasound and alpha-fetoprotein among Alaska Native people, 1983–2012 (2016) (4)
Hepatitis C in pregnant American Indian and Alaska Native women; 2003-2015 (2019) (4)
The relationship between previous antimicrobial use, antimicrobial resistance and treatment outcome among Alaskans treated for Helicobacter pylori infection (2019) (3)
Predicting treatment eligibility for hepatitis B in low income regions: Can treatment scores without HBV DNA testing serve the purpose? (2018) (3)
Risk Factors for Helicobacter pylori Resistance (2004) (3)
Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C. (2016) (3)
The role of primary care physician assistants in managing chronic hepatitis B (2014) (2)
Reply: HEPATOLOGY, Vol. XX, No. X, 2016 (2016) (2)
Letter: hepatitis B surface seroclearance does reduce the risk of hepatocellular carcinoma ‐ authors' reply (2016) (2)
Liver disease in the indigenous populations of the Arctic, sub- (2006) (2)
Recent advances in managing hepatitis B (2010) (2)
Response to Editorial (2018) (2)
Laboratory Evaluation of Modified Ristroph Traveling Screens for Protecting Fish at Cooling Water Intakes (2006) (2)
Two Key Components to Address Chronic Hepatitis B in Children: Detection and Prevention. (2015) (2)
Reply (2018) (2)
Nifedipine--induced hepatitis. (1986) (2)
577 A lookback program to notify persons who received blood products in a neonatal intensive care unit before July 1992 of their risk for hepatitis C virus (HCV) infection: results for those with managed care providers versus private sector providers (2003) (1)
Combination of Pegylated Interferon and Tenofovir for Hepatitis B Treatment: Screening and Counseling of Patients are Warranted. (2016) (1)
Screening for Hepatitis B (2013) (1)
Immunization of newborns of HBsag‐ positive mothers: A successful first step in control of hepatitis B virus in Taiwan (1989) (1)
Unnecessary Prehospital Spinal Immobilization (2005) (1)
937 A prospective study of abnormal serum aminotransferase levels in a population-based cohort of 1057 persons chronically infected with hepatitis B virus (2003) (1)
Patterns of HBeAg and HBsAg clearance among a treatment‐naive Alaskan Cohort in a long‐term observational study (2020) (1)
B型肝炎ウイルス(HBV)慢性感染者におけるB型肝炎表面抗原の陰性化と肝細胞癌のリスク (2010) (1)
Hepatitis B virus elimination status and strategies in circumpolar countries, 2020 (2021) (1)
What should we clinicians do for healthy, asymptomatic, hbsag‐positive carriers? (1993) (1)
An ELISA test for diagnosis and screening of echinococcus multilocularis in a high-risk Inupiat Eskimo population. (1988) (1)
Impact of Programs to Manage Alaska Native Patients with Chronic Hepatitis B and C in Urban and Remote Rural Areas using a Data Base Registry. (2014) (1)
Hepatocellular carcinoma and hepatitis B virus: family matters. (2013) (1)
Summary of available surveillance data on hepatitis C virus infection from eight Arctic countries, 2012 to 2014 (2018) (1)
202 Hepatitis B virus genotypes in Alaska natives with hepatocellular carcinoma: preponderance of genotype F (2003) (1)
Workshop on hepatitis B in circumpolar countries. Summary of the hepatitis B workshop. (1988) (1)
NEGATIVE IMMUNE REGULATOR TIM-3 IS OVEREXPRESSED ON INTRAHEPATIC AND PERIPHERAL T CELLS IN CHRONIC HCV INFECTION AND ITS BLOCKADE RESCUES DYSFUNCTIONAL CD4+AND CD8+T CELLS (2009) (1)
Hepatitis B Vaccination, Screening, and Linkage to Care (2018) (1)
blood culture yielded S. pneumoniae that was susceptible to both Sepsis Due to Streptococcus pneumoniae in a Patient with (1999) (0)
Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C (2016) (0)
Faculty of 1000 evaluation for Integration of hepatitis B virus S gene impacts on hepatitis B surface antigen levels in patients with antiviral therapy. (2018) (0)
Developing and implementing a program of grand rounds for internists that is free of commercial bias. (2003) (0)
390 Steatosis and hepatitis C in a native American population (2003) (0)
587 Retrospective study correlating the prometheus liver fibrosis panel with findings of fibrosis on percutaneous liver biopsy specimens in Alaska natives with hepatitis C (2003) (0)
Interpreting hepatitis B surface antigen levels: useful clinical test or just another confusing assay? (2012) (0)
Vaccination Status of Alaska Native Persons With Hepatitis A Virus Infection-Alaska, 1996-2018. (2020) (0)
Faculty Opinions recommendation of Screening for hepatitis C virus infection in adults: a systematic review for the U.S. Preventive Services Task Force. (2013) (0)
Faculty Opinions recommendation of Hepatitis C virus reactivation in patients receiving cancer treatment: A prospective observational study. (2018) (0)
T1802 Genotyping of vacA and CagA from Helicobacter pylori Isolates in Alaska (2008) (0)
CLINICAL—LIVER, PANCREAS, AND BILIARY TRACT Adverse Outcomes in Alaska Natives Who Recovered From or Have Chronic Hepatitis C Infection (2010) (0)
Reply: (2007) (0)
Faculty Opinions recommendation of A randomized controlled trial of an integrated alcohol reduction intervention in patients with hepatitis C infection. (2020) (0)
Evaluation of fish behavioural barriers (1998) (0)
during Interferon Therapy and Natural Infection Interferon Sensitivity-Determining Region Hypervariable Region 1 and the Putative Evolution of Hepatitis C Virus Quasispecies in (2013) (0)
Faculty Opinions recommendation of Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. (2015) (0)
Faculty Opinions recommendation of Reducing risk for mother-to-infant transmission of hepatitis C virus: a systematic review for the U.S. Preventive Services Task Force. (2013) (0)
The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals (2021) (0)
201 Hepatitis B associated vasculitis in Alaska natives: Viral genotype, clinical and serologic outcome and incidence of new cases over time after initiation of hepatitis B vaccination program (2003) (0)
High frequency of clarithromycin and metronidazole resistance in Helicobacter pylori isolates from Alaska natives (2003) (0)
Viral Hepatitis: Free Papers (2014) (0)
Reply: (2007) (0)
T1021 Liver Biopsy Results and Risk Factors for Advanced Liver Disease in a Large Population-Based Cohort of HCV Carriers Undergoing Liver Biopsy (2008) (0)
Reply: (2007) (0)
Update on Diagnosis and Treatment within the Four Clinical Phases of Chronic Hepatitis B Infection (2011) (0)
Table of contents (2016) (0)
Comparing the Cost-Effectiveness of Two Approaches to Hepatocellular Carcinoma (HCC) Surveillance in Persons with Chronic Hepatitis B (CHB) Virus Infection. (2014) (0)
Reply (2003) (0)
Long-Term Protection and Antibody Levels 35 Years after Primary Immunization Series with Hepatitis B Vaccine and Response to a Booster Dose in Those Persons Who Lost Antibody (2021) (0)
Letter: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance – authors’ reply (2017) (0)
23rd Annual Conference of APASL March 12–15, 2014, Brisbane, Australia (2014) (0)
Faculty Opinions recommendation of Combination of Entecavir/Peginterferon Alfa-2a in Children With Hepatitis B e Antigen-Positive Immune Tolerant Chronic Hepatitis B Virus Infection. (2019) (0)
Hepatitis B Virus Core Variants, Liver Fibrosis, and Hepatocellular Carcinoma (2019) (0)
Preventing Perinatal Transmission of Hepatitis B Necessitates Consideration of Antiviral Treatment in Pregnancy (2018) (0)
Mortality among Alaska Native Adults with Confirmed Hepatitis C Virus Infection Compared with the General Population in Alaska, 1995–2016 (2022) (0)
Reply: (2002) (0)
An Evidence-based Practical Guide to Vaccination for Hepatitis B Virus (2022) (0)
Multi-scale Replication of Small Intestine Basement Membrane via Chemical Vapor Deposition (2010) (0)
Reply (2016) (0)
MortalityCausedbyChronicLiverDiseaseAmong AmericanIndiansandAlaskaNativesintheUnitedStates, 1999-2009 (2014) (0)
Preliminary assessment of hepatitis B-specific cellular immunity amongst a longitudinal vaccine cohort demonstrates evidence of natural exposure. (VAC11P.1110) (2015) (0)
European Helicobacter Study Group: Abstracts of the XXIVth International Workshop on Helicobacter and related bacteria in chronic digestive inflammation and gastric cancer (2011) (0)
402 Clinical and demographic features of hepatitis C-infected Alaska natives with persistently normal, persistantly elevated or fluxuating alanine transaminase levels (2003) (0)
Poster Sessions (2013) (0)
88 Reported hepatitis c infection in american indian and alaska native mothers, 2011–2015 (2018) (0)
Helicobacter pylori Antimicrobial Resistance and Treatment for Alaska Native People (2011) (0)
Reply (2021) (0)
Cost-effectiveness analysis of hepatocellular carcinoma screening by combinations of ultrasound and alpha-fetoprotein among Alaska Native people, 1983-2012. (2016) (0)
Faculty Opinions recommendation of Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. (2020) (0)
Population-Based Longitudinal Study of Hepatitis B “e” Antigen Negative persons with Chronic Hepatitis B: Level of HBV DNA and Liver Disease (2015) (0)
Australian tax planning, with precedents (1961) (0)
Reply (2016) (0)
Evaluation of Modular and Scalable Downstream Passage Systems for Silver American Eels (2021) (0)
Prevention of viral hepatitis in circumpolar populations. (1991) (0)
544 INTRA-HOUSEHOLD TRANSMISSION HEPATITIS B VIRUS (HBV) INFECTION (1985) (0)
Abstract: The evaluation of production potentials of demethanation wells utilizing “hot-wire” gas detection methods (1982) (0)
Seasonal Variations in Sensitivity of Microorganisms to Antibiotics (1955) (0)
Observed increases in CD4:CD8 and TIGIT expression during sofosbuvir-based therapy in a longitudinal hepatitis C cohort (2018) (0)
Treatment eligibility in Alaska Native and American Indian persons with hepatitis C virus infection. (2012) (0)
Treatment eligibility in Alaska Native and American Indian persons with hepatitis C virus infection. (2012) (0)
Faculty Opinions recommendation of Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease. (2013) (0)
Faculty Opinions recommendation of Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. (2013) (0)
Photoinitiated Chemical Vapor Deposition of Hydrogels for Use as Cell Culture Substrates (2010) (0)
Use of Angiotensin-Converting Enzyme Inhibitors in Heart Failure and Renal Insufficiency (2004) (0)

This paper list is powered by the following services:

Brian Jarrett Mcmahon's Academic­Influence.com Rankings

Brian Jarrett Mcmahon's Degrees

Why Is Brian Jarrett Mcmahon Influential?

Brian Jarrett Mcmahon's Published Works

Published Works

Brian Jarrett Mcmahon's AcademicInfluence.com Rankings